All In Biotech

Free tool

FAERS Monitor: Nexviazyme

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761194 or its brand name (Nexviazyme, Avalglucosidase Alfa-Ngpt). Reports on generic versions are filed under their own applications.

Reports

998

Serious

210

21% of reports

Hospitalization

113

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug specific antibody present150
  • off label use100
  • weight increased64
  • inappropriate schedule of product administration52
  • weight decreased46
  • pyrexia39
  • fatigue36
  • dyspnoea35
  • condition aggravated32
  • illness32
  • fall28
  • headache28
  • pneumonia26
  • cough24
  • malaise24

Reports by year received

View as table
YearReports
202122
2022148
2023195
2024212
2025221
2026200

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,161 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug specific antibody presentSignal150497.5428.472,155
illnessSignal326.54.7146
inappropriate schedule of product administrationSignal526.14.7218
weight increasedSignal646.04.8266
weight decreasedSignal463.52.680
off label useSignal1002.42.084
pyrexiaSignal392.41.730
condition aggravatedSignal322.21.621
cough241.81.28
fall281.81.29
pneumonia261.71.27
dyspnoea351.30.92
malaise241.20.80
fatigue361.00.70
headache280.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.